Sue Wang

Sue’s recent experience has involved technologies related to: small molecule pharmaceuticals and treatment methods; DNA sequencing; gene editing; RNA interference; antibody therapeutics; protein manufacturing processes; cancer immunotherapy; and T-cell therapies. Representative litigation matters include:

• Representing biopharmaceutical company in multi-district patent litigation under the BPCIA involving proposed biosimilars to company’s antibody biologic. Leading the development of core theories and strategy across cases in several jurisdictions including the District of New Jersey. One case settled favorably after a multi-day evidentiary hearing on a motion for preliminary injunction.
• Represented biopharmaceutical company in Hatch-Waxman litigation involving small-molecule psoriasis drug. As part of trial team in the District of New Jersey, helped secure ruling upholding validity of key patents. As part of appellate team, helped secure affirmance at the Federal Circuit. Awarded “Patent Impact Case of the Year” by LMG Life Sciences in 2023.
• Represented biopharmaceutical company in patent litigations involving biosimilars to the company’s blockbuster fusion protein biologic. As part of trial team, helped secure ruling upholding patent validity following a two-week bench trial in the District of New Jersey. As part of appellate team, helped secure affirmance at the Federal Circuit. Awarded “Impact Case of the Year” by LMG Life Sciences in 2020.
• Represented pharmaceutical company in multiple patent suits involving Factor VIII products. As part of trial team, helped secure a jury victory for the patent owner that resulted in one of the highest biotech verdicts in the District of Delaware. As part of appellate team, helped secure affirmance from the Federal Circuit on all issues. Cases settled favorably. Recognized in National Law Journal’s “Verdicts Hall of Fame” and awarded “Impact Case of the Year” by LMG Life Sciences in 2019.
• Representing multiple software developers in the Northern District of California in patent infringement lawsuits brought by non-practicing entity.
• Represented biopharmaceutical company in first-of-its-kind declaratory judgment patent litigation under the Biologics Price Competition and Innovation Act (BPCIA), successfully securing dismissal for lack of an Article III case or controversy.